Tilt Investment Management Holdings PBC Sells 343 Shares of Becton, Dickinson and Company (NYSE:BDX)

Tilt Investment Management Holdings PBC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 23.0% in the 4th quarter, Holdings Channel reports. The firm owned 1,150 shares of the medical instruments supplier’s stock after selling 343 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Becton, Dickinson and Company were worth $280,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BDX. Householder Group Estate & Retirement Specialist LLC bought a new stake in Becton, Dickinson and Company during the third quarter valued at $25,000. OFI Invest Asset Management purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. Fortitude Family Office LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $35,000. Venturi Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 138 shares in the last quarter. Finally, Advisors Asset Management Inc. purchased a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $40,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research reports. Barclays boosted their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James upped their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX traded down $0.32 on Thursday, reaching $231.89. 403,671 shares of the company’s stock traded hands, compared to its average volume of 1,400,148. The stock has a market cap of $66.99 billion, a PE ratio of 55.04, a P/E/G ratio of 1.91 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The stock has a 50-day simple moving average of $240.34 and a 200 day simple moving average of $242.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.98 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.64%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 90.05%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.